Page 92 - Prostate News Today

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced

Pancreatic cancer is one of the deadliest types of cancer-;in the U.S., it is estimated that over 88 percent of people will die from the disease within five years of their diagnosis.

LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L), on Wednesday, announced that Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

Researchers have described prostate cancer cell dynamics at a single-cell resolution throughout the course of the disease, from the first stages to the point of androgen independence, where the tumour no longer responds to hormone restriction therapy.

The FINANCIAL -- Cambridge scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk. CanRisk-Prostate, developed by researchersThe FINANCIAL -- Cambridge scientists have created a comprehensive tool for predicting an individual’s risk of develo...

Some patients with prostate cancer have genetic mutations that may impact their treatment. A comprehensive, on-site genetic testing program, pioneered by urologists, could help to close the gap for this underutilized resource, reports a study in Urology Practice®, an Official Journal of the American Urological Association (AUA).

Throughout the course of the disease, from the first stages to the point of androgen independence, where the tumour ceases to respond to hormone restriction therapy, researchers have characterised prostate cancer cell dynamics at a single-cell resolution.

[bleep]. >> greg: thats right. >> rob: seriously im doing a lot of traveling right now and the places i see the most suspiciously large women are always the liberal strong holds like new york, san francisco et cetera. this is the game the left plays with language, they redefine it keep moving the goal posts and then get us used to it so next thing we know applebees isnt having ladies night theyre having people who men straight night. right? so this is -- >> kat: sorry, thats just different. >> r...

Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour no longer responds to hormone deprivation therapy.